These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 20189638)

  • 1. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.
    Mathers BM; Degenhardt L; Ali H; Wiessing L; Hickman M; Mattick RP; Myers B; Ambekar A; Strathdee SA;
    Lancet; 2010 Mar; 375(9719):1014-28. PubMed ID: 20189638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
    Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L
    Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.
    Nelson PK; Mathers BM; Cowie B; Hagan H; Des Jarlais D; Horyniak D; Degenhardt L
    Lancet; 2011 Aug; 378(9791):571-83. PubMed ID: 21802134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
    Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S
    Lancet Glob Health; 2017 Dec; 5(12):e1192-e1207. PubMed ID: 29074409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries.
    Petersen Z; Myers B; van Hout MC; Plüddemann A; Parry C
    Harm Reduct J; 2013 Aug; 10():13. PubMed ID: 23957896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries.
    Degenhardt L; Mathers BM; Wirtz AL; Wolfe D; Kamarulzaman A; Carrieri MP; Strathdee SA; Malinowska-Sempruch K; Kazatchkine M; Beyrer C
    Int J Drug Policy; 2014 Jan; 25(1):53-60. PubMed ID: 24113623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review.
    Colledge-Frisby S; Ottaviano S; Webb P; Grebely J; Wheeler A; Cunningham EB; Hajarizadeh B; Leung J; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Degenhardt L
    Lancet Glob Health; 2023 May; 11(5):e673-e683. PubMed ID: 36996860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coverage to curb the emerging HIV epidemic among injecting drug users in Pakistan: delivering prevention services where most needed.
    Emmanuel F; Fatima M
    Int J Drug Policy; 2008 Apr; 19 Suppl 1():S59-64. PubMed ID: 18281206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia.
    Aceijas C; Hickman M; Donoghoe MC; Burrows D; Stuikyte R
    Addiction; 2007 Aug; 102(8):1244-50. PubMed ID: 17565564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
    Alistar SS; Owens DK; Brandeau ML
    PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward.
    Wolfe D; Carrieri MP; Shepard D
    Lancet; 2010 Jul; 376(9738):355-66. PubMed ID: 20650513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug.
    Tempalski B; Cooper HL; Friedman SR; Des Jarlais DC; Brady J; Gostnell K
    Int J Drug Policy; 2008 Apr; 19 Suppl 1(Suppl 1):S47-58. PubMed ID: 18295468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV transmission in Bangladesh: an analysis of IDU programme coverage.
    Reddy A; Hoque MM; Kelly R
    Int J Drug Policy; 2008 Apr; 19 Suppl 1():S37-46. PubMed ID: 18207724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention.
    Strathdee SA; Shoptaw S; Dyer TP; Quan VM; Aramrattana A;
    Curr Opin HIV AIDS; 2012 Jul; 7(4):320-5. PubMed ID: 22498479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study.
    Cepeda JA; Eritsyan K; Vickerman P; Lyubimova A; Shegay M; Odinokova V; Beletsky L; Borquez A; Hickman M; Beyrer C; Martin NK
    Lancet HIV; 2018 Oct; 5(10):e578-e587. PubMed ID: 30033374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous drug use and the spread of HIV; an international perspective].
    Meijerink H; van Crevel R; van der Ven AJ
    Ned Tijdschr Geneeskd; 2013; 157(21):A5690. PubMed ID: 23693006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of high-risk drug use and coverage of opioid substitution treatment and needle and syringe programs in Lithuania in 2015-2016: A multi-method estimation study.
    Thanki D; Mravčík V; Běláčková V; Mačiulytė D; Zábranský T; Širvinskienė A; Subata E; Lorenzo-Ortega R
    J Subst Abuse Treat; 2021 Mar; 122():108229. PubMed ID: 33509418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis.
    Aghaei AM; Gholami J; Sangchooli A; Rostam-Abadi Y; Olamazadeh S; Ardeshir M; Baheshmat S; Shadloo B; Taj M; Saeed K; Rahimi-Movaghar A
    Lancet Glob Health; 2023 Aug; 11(8):e1225-e1237. PubMed ID: 37474230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5").
    Aceijas C; Oppenheimer E; Stimson GV; Ashcroft RE; Matic S; Hickman M
    Addiction; 2006 Sep; 101(9):1246-53. PubMed ID: 16911723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.